Core Insights - AccuStem Sciences, Inc. has initiated a pilot study agreement with NSABP to evaluate the StemPrintER test in a subset of patients from the B-32 cohort, aiming to confirm its predictive capabilities across the full study cohort [1][3] Group 1: StemPrintER Test - The StemPrintER test analyzes 20 genes to stratify early-stage breast cancer patients based on their recurrence risk, measuring the "stemness" of tumors, which may indicate cancer progression and treatment response [2] - Patients with "High Stemness" are up to 4 times more likely to experience distant recurrence compared to "Low Stemness" patients, highlighting the test's prognostic utility [2] Group 2: Collaboration and Study Details - The partnership with NSABP aims to validate preliminary findings that suggest StemPrintER has predictive utility in surgical settings, which could significantly impact surgical planning for breast cancer patients [3][4] - The NSABP B-32 trial, which enrolled over 5,000 patients from 1999 to 2004, demonstrated that sentinel lymph node resection (SLNR) is equivalent to full axillary lymph node dissection (ALND) in terms of overall survival while resulting in fewer side effects [3] Group 3: Company Vision and Goals - AccuStem is focused on optimizing outcomes and quality of life for cancer patients through proprietary molecular testing that addresses unmet clinical needs from screening to treatment [5] - The company believes that by exploring novel disease pathways like tumor "stemness," its tools will enhance understanding of cancer biology, leading to more informed decision-making in patient care [5]